Despite recent advances in immunotherapy, certain subtypes of colorectal cancer, such as those that are MSI-high, dMMR of TMB-H, remain a treatment challenge. Moreover, the optimal therapeutic approach for colorectal cancer in the neoadjuvant setting remains elusive, with recent data pointing to combination approaches as potentially beneficial.